The experimental study was performed to determine the efficacy of a mycotoxin detoxification agent (MS) at a concentration of 0.2% in reducing the toxicity of aflatoxin B1 (AFB1) and ochratoxin A (OTA), alone or in combination, and to examine its effect on performance, pathohistological (PH) changes, and residues of these toxins in the tissues of broiler chicks. A total of 88 broilers were divided into eight equal groups: group C, the control group (fed a commercial diet without any additives); group MS, which received the mycotoxin detoxification agent (MS) (supplemented with 0.2%); group E I (0.2 mg AFB1/kg of diet); group E II (0.2 mg AFB1/kg of diet + MS 0.2%); group E III (1.5 mg OTA/kg of diet); group E IV (1.5 mg OTA/kg of diet + 0.2% MS); group E V (combination of 0.2 mg AFB1/kg, 1.5 mg OTA/kg of diet); and group E VI (combination of 0.2 mg AFB1/kg, 1.5 mg OTA toxin + 0.2% MS). Results show that feed containing AFB1 and OTA, individually or in combination, negatively affects health, production results, and PH changes in tissues, as well as the presence of mycotoxin residues in the liver and breast muscles of poultry. The addition of a new multicomponent preparation for the detoxification of MS mycotoxins in feed with AFB1 and OTA individually and in combination had a positive effect on TM (BW), growth (BWG), consumption and FCR conversion coefficient, and microscopic lesions in organs. The concentration of OTA residues in the liver and chest muscles was significantly lower in chickens fed a diet with the addition of 0.2% MS of the mycotoxin detoxification preparation.
Trailović et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: